Xinvento
Xinvento is a privately held, pre-clinical biotech company founded in 2021 in Amsterdam, Netherlands. It develops proprietary small-molecule drug candidates aimed at treating Congenital Hyperinsulinism (CHI), a rare pediatric disease with limited therapeutic options.
- Company typePrivate
- Founded2021
- HeadquartersAmsterdam, Netherlands
- Headcount1–10
- GTM typeB2C
- OfferingServices
What Xinvento does
Xinvento is an early-stage biotechnology company founded in 2021 and headquartered in Amsterdam, Netherlands. The company is focused on developing a treatment for Congenital Hyperinsulinism (CHI), a rare disease that primarily affects children and for which current effective therapeutic options are limited. Its core technology consists of designing and testing proprietary molecules intended to serve as drug candidates for CHI patients, with the stated goal of identifying viable candidates within roughly one year of seed funding.
The company operates in a pre-clinical, pre-revenue drug discovery phase. As of the available data, Xinvento has not disclosed any commercial products, pricing models, marketing or distribution channels, partnerships, or named customers. The company's public web presence (xinvento.com) is a parked domain registered with Hostnet, a Dutch hosting provider, indicating no active commercial-facing web operations. No management team, board, scientific advisory board, institutional investors, patents, or regulatory milestones have been publicly disclosed. The firm operates with a headcount of 1–10 employees.
Xinvento's business model is conventional for a pre-clinical biotech: it raises external capital to fund R&D aimed at producing a viable drug candidate, after which commercialization pathways (out-licensing, partnership, or independent development) would be evaluated. To date, the company has completed one seed funding round in April 2022, the amount of which was not publicly disclosed. There is no current revenue, no pricing model, and no articulated path to market. The company is privately held, with no parent company or disclosed ownership structure beyond founders.
Xinvento firmographics
Firmographics- Name
- Xinvento
- Website
- https://xinvento.com
- Company type
- Private
- Founded year
- 2021
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Xinvento is a privately held, pre-clinical biotech company founded in 2021 in Amsterdam, Netherlands. It develops proprietary small-molecule drug candidates aimed at treating Congenital Hyperinsulinism (CHI), a rare pediatric disease with limited therapeutic options.
- Ownership category
- akta.pro rank
Xinvento industry classification
Industry- Product category
- Rare Disease Therapeutics
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical and Medicine Manufacturing (32541)
- SIC
- Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Rare Pediatric & Congenital Disorder Therapies (HLAIAIAN)
Keywords
Where Xinvento is headquartered
LocationHeadquarters
- HQ city
- Amsterdam
- HQ country
- Netherlands
- HQ region
- Europe
Markets served
Xinvento business model
Business model- GTM type
- B2C
- Offering type
- Services
- Cost components
- Technology or R&D, Personnel, Operations
Xinvento product offering
Product offeringCore offering
Xinvento is developing proprietary molecules aimed at producing drug candidates to treat Congenital Hyperinsulinism (CHI), a rare disease with limited therapeutic options. The company is in the preclinical discovery stage, having completed a seed funding round intended to identify drug candidates within one year.
Product overview
Xinvento is an early-stage biotech company founded in 2021 that is focused on developing a treatment for Congenital Hyperinsulinism (CHI). The company completed a seed funding round to support the design and testing of proprietary molecules to identify drug candidates within a year. No specific named products or services were identified in the available source data.
Differentiator
Problem solved
Functional benefit
Quantifiable outcome
- Goal to identify drug candidates within one year of seed funding
Companies that use Xinvento
Customer profileSegments1 record
Ideal customer profiles1 record
Xinvento technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Xinvento partnerships and signals
Strategic signalScale indicators1 record
Recent moves2 records
Expansion highlights2 records
Xinvento competitors and assessment
Company assessmentBroad incumbents
- Swedish Orphan Biovitrum (Sobi): Sobi is a European-headquartered rare disease specialty pharma with strong presence in rare pediatric and metabolic disorders. Relevant comparator given Xinvento's Netherlands location and rare pediatric focus.
- Ultragenyx Pharmaceutical: Ultragenyx is a commercial-stage rare disease company with established rare pediatric franchises. Comparable market (rare pediatric disease) and overlapping therapeutic targets, but considerably larger and broader in scope.
- BioMarin Pharmaceutical: BioMarin is a leading rare disease biotech with multiple approved rare pediatric therapies. Operates in the same orphan/rare pediatric disease commercial space Xinvento targets, with deep regulatory and commercial infrastructure.
Emerging players
- Crinetics Pharmaceuticals: Crinetics focuses on rare endocrine diseases with a small-molecule discovery platform. Comparable to Xinvento in rare endocrine target space and small-molecule R&D approach, though it covers broader indications.
- Tiburio Therapeutics: Tiburio is a clinical-stage rare endocrine disease biotech. Comparable as a small rare-disease company with similar stage profile and a focus on underserved endocrine indications.
- Eiger BioPharmaceuticals: Eiger is a clinical-stage rare disease biotech with multiple rare disease programs. Comparable as a small rare-disease focused development-stage company pursuing orphan indications.
Direct peers
- Rezolute: Rezolute is developing RZ358, an anti-insulin receptor antibody for congenital hyperinsulinism — the same indication as Xinvento's program. Most directly comparable peer given identical therapeutic focus on CHI.
- Soleno Therapeutics: Soleno is advancing diazoxide choline (DCCR) for hyperinsulinism, including congenital forms. Directly comparable to Xinvento as a clinical-stage rare disease company targeting hyperinsulinemic disorders.
Market position
Strengths4 records
Weaknesses5 records
Competitive moat2 records
Key risks5 records
Key highlights4 records
Customer concentration
Xinvento social profiles
Digital presenceXinvento financial estimates
Financial estimateRevenue estimate
Valuation estimate
Xinvento leadership team
Management profileNumber of profiles
Xinvento funding detail
Funding detailFunding overview
Funding rounds1 record
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Xinvento M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Xinvento
What does Xinvento do?
Xinvento is developing proprietary molecules aimed at producing drug candidates to treat Congenital Hyperinsulinism (CHI), a rare disease with limited therapeutic options. The company is in the preclinical discovery stage, having completed a seed funding round intended to identify drug candidates within one year.
Is Xinvento a public or private company?
Xinvento is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Xinvento founded?
Xinvento was founded in 2021. It employs 1 to 10 people.
Where is Xinvento based?
Xinvento is headquartered in Amsterdam, Netherlands, in the Europe region.
Who are Xinvento's main competitors?
Broad incumbents on record are Swedish Orphan Biovitrum (Sobi), Ultragenyx Pharmaceutical and BioMarin Pharmaceutical. Emerging players are Crinetics Pharmaceuticals, Tiburio Therapeutics and Eiger BioPharmaceuticals. Direct peers are Rezolute and Soleno Therapeutics.
Does Xinvento have an API?
No public API is recorded for Xinvento.
What industry is Xinvento in?
Xinvento's product category is Rare Disease Therapeutics. Its primary akta.pro industry code is HLAIAIAN, Rare Pediatric & Congenital Disorder Therapies. Its NAICS code is 541714 and its SIC code is 2834.